VBL Therapeutics to Present Positive Phase 1/2 Data for VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at ASCO Annual Meeting
TEL AVIV, Israel, May 13, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that principal investigator, Richard Penson, M.D., M.R.C.P., will present interim data from the ongoing Phase 1/2 clinical trial of lead product candidate, VB-111, for the treatment of platinum-resistant Mullerian cancer, in a poster presentation on Saturday, May 30, 2015 at the American Society for Clinical Oncology (ASCO) 2015 Annual Meeting. The reported data will include results in patients with recurrent platinum-resistant Mullerian cancer treated with multiple doses of VB-111 and weekly paclitaxel.
As the first highly targeted anti-angiogenic agent for the specific inhibition of tumor vascular growth to use VBL's Vascular Targeting System(TM) for cancer therapy, VB-111 has the potential to treat a range of solid tumor indications by selectively targeting the blood vessels required for tumor growth and inducing apoptosis of cells in those blood vessels. VBL recently reported positive, statistically significant data evaluating the efficacy of VB-111 for the treatment of recurrent glioblastoma (rGBM), and expects to initiate a pivotal Phase 3 study in rGBM under a Special Protocol Assessment with the U.S. Food and Drug Administration in mid-2015.
Details of the presentation are as follows:
Abstract:#5542
Title: A phase 1/2 trial of multiple dose VB-111 and weekly paclitaxel in recurrent platinum-resistant Mullerian cancer
Time: Saturday, May 30, 2015, 1:15 PM -- 4:45 PM CT
Session: Poster Session: Gynecologic Cancer
Authors: Richard T Penson MD MRCP (Massachusetts General Hospital), Allison J Ambrosio BA (Massachusetts General Hospital), Daphne Suzin BA BSc (Massachusetts General Hospital), Siobhan A. Collins BA (Dana Farber Cancer Institute), Michael J Birrer PhD (Massachusetts General Hospital), Suzanne Berlin DO (Dana Farber Cancer Institute), Yael Cohen MD (VBL Therapeutics).
